<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 20:19:17 -0700</creation_date>
  <update_date>2013-01-15 20:19:17 -0700</update_date>
  <accession>HMDBP09086</accession>
  <secondary_accessions>
    <accession>14830</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>HH1</synonym>
    <synonym>Sodium channel protein cardiac muscle subunit alpha</synonym>
    <synonym>Sodium channel protein type V subunit alpha</synonym>
    <synonym>Voltage-gated sodium channel subunit alpha Nav1.5</synonym>
  </synonyms>
  <gene_name>SCN5A</gene_name>
  <general_function>Involved in ion channel activity</general_function>
  <specific_function>This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant Na(+) channel isoform. This channel is responsible for the initial upstroke of the action potential in the electrocardiogram</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00588</accession>
      <name>Sodium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01850</accession>
      <name>Verapamil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14338</accession>
      <name>Indecainide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14388</accession>
      <name>Ranolazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13895</accession>
      <name>3',4'-Dihydrodiol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14425</accession>
      <name>Disopyramide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14426</accession>
      <name>Lidocaine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14523</accession>
      <name>Mexiletine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14616</accession>
      <name>Hexylcaine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14668</accession>
      <name>Dibucaine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14704</accession>
      <name>Carbamazepine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13961</accession>
      <name>O-Desmethylverapamil (D-702)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14818</accession>
      <name>Moricizine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14878</accession>
      <name>Riluzole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14888</accession>
      <name>Prilocaine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14892</accession>
      <name>Ethotoin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14914</accession>
      <name>Oxcarbazepine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15006</accession>
      <name>Benzonatate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15043</accession>
      <name>Cocaine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15044</accession>
      <name>Quinidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15045</accession>
      <name>Zonisamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15169</accession>
      <name>Procainamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15189</accession>
      <name>Tocainide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15313</accession>
      <name>Propafenone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15326</accession>
      <name>Flecainide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15359</accession>
      <name>Encainide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15417</accession>
      <name>Fosphenytoin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15436</accession>
      <name>Quinidine barbiturate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15495</accession>
      <name>Ajmaline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15498</accession>
      <name>Aprindine</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>cation channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>sodium channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>voltage-gated sodium channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>substrate-specific transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cation transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>monovalent inorganic cation transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>sodium ion transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>transmembrane transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>establishment of localization</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>ion transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>macromolecular complex</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>protein complex</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>ion channel complex</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cation channel complex</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>sodium channel complex</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>voltage-gated sodium channel complex</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:3</chromosome_location>
    <locus>3p21</locus>
    <gene_sequence>&gt;6051 bp
ATGGCAAACTTCCTATTACCTCGGGGCACCAGCAGCTTCCGCAGGTTCACACGGGAGTCC
CTGGCAGCCATCGAGAAGCGCATGGCAGAGAAGCAAGCCCGCGGCTCAACCACCTTGCAG
GAGAGCCGAGAGGGGCTGCCCGAGGAGGAGGCTCCCCGGCCCCAGCTGGACCTGCAGGCC
TCCAAAAAGCTGCCAGATCTCTATGGCAATCCACCCCAAGAGCTCATCGGAGAGCCCCTG
GAGGACCTGGACCCCTTCTATAGCACCCAAAAGACTTTCATCGTACTGAATAAAGGCAAG
ACCATCTTCCGGTTCAGTGCCACCAACGCCTTGTATGTCCTCAGTCCCTTCCACCCCATC
CGGAGAGCGGCTGTGAAGATTCTGGTTCACTCGCTCTTCAACATGCTCATCATGTGCACC
ATCCTCACCAACTGCGTGTTCATGGCCCAGCACGACCCTCCACCCTGGACCAAGTATGTC
GAGTACACCTTCACCGCCATTTACACCTTTGAGTCTCTGGTCAAGATTCTGGCTCGAGGC
TTCTGCCTGCACGCGTTCACTTTCCTTCGGGGCCCATGGAACTGGCTGGACTTTAGTGTG
ATTATCATGGCGTATGTATCAGAAAATATAAAACTAGGCAATTTGTCGGCTCTTCGAACT
TTCAGAGTCCTGAGAGCTCTAAAAACTATTTCAGTTATCCCAGGGCTGAAGACCATCGTG
GGGGCCCTGATCCAGTCTGTGAAGAAGCTGGCTGATGTGATGGTCCTCACAGTCTTCTGC
CTCAGCGTCTTTGCCCTCATCGGCCTGCAGCTCTTCATGGGCAACCTAAGGCACAAGTGC
GTGCGCAACTTCACAGCGCTCAACGGCACCAACGGCTCCGTGGAGGCCGACGGCTTGGTC
TGGGAATCCCTGGACCTTTACCTCAGTGATCCAGAAAATTACCTGCTCAAGAACGGCACC
TCTGATGTGTTACTGTGTGGGAACAGCTCTGACGCTGGGACATGTCCGGAGGGCTACCGG
TGCCTAAAGGCAGGCGAGAACCCCGACCACGGCTACACCAGCTTCGATTCCTTTGCCTGG
GCCTTTCTTGCACTCTTCCGCCTGATGACGCAGGACTGCTGGGAGCGCCTCTATCAGCAG
ACCCTCAGGTCCGCAGGGAAGATCTACATGATCTTCTTCATGCTTGTCATCTTCCTGGGG
TCCTTCTACCTGGTGAACCTGATCCTGGCCGTGGTCGCAATGGCCTATGAGGAGCAAAAC
CAAGCCACCATCGCTGAGACCGAGGAGAAGGAAAAGCGCTTCCAGGAGGCCATGGAAATG
CTCAAGAAAGAACACGAGGCCCTCACCATCAGGGGTGTGGATACCGTGTCCCGTAGCTCC
TTGGAGATGTCCCCTTTGGCCCCAGTAAACAGCCATGAGAGAAGAAGCAAGAGGAGAAAA
CGGATGTCTTCAGGAACTGAGGAGTGTGGGGAGGACAGGCTCCCCAAGTCTGACTCAGAA
GATGGTCCCAGAGCAATGAATCATCTCAGCCTCACCCGTGGCCTCAGCAGGACTTCTATG
AAGCCACGTTCCAGCCGCGGGAGCATTTTCACCTTTCGCAGGCGAGACCTGGGTTCTGAA
GCAGATTTTGCAGATGATGAAAACAGCACAGCGGGGGAGAGCGAGAGCCACCACACATCA
CTGCTGGTGCCCTGGCCCCTGCGCCGGACCAGTGCCCAGGGACAGCCCAGTCCCGGAACC
TCGGCTCCTGGCCACGCCCTCCATGGCAAAAAGAACAGCACTGTGGACTGCAATGGGGTG
GTCTCATTACTGGGGGCAGGCGACCCAGAGGCCACATCCCCAGGAAGCCACCTCCTCCGC
CCTGTGATGCTAGAGCACCCGCCAGACACGACCACGCCATCGGAGGAGCCAGGCGGCCCC
CAGATGCTGACCTCCCAGGCTCCGTGTGTAGATGGCGTCGAGGAGCCAGGAGCACGGCAG
CGGGCCCTCAGCGCAGTCAGCGTCCTCACCAGCGCACTGGAAGAGTTAGAGGAGTCTCGC
CACAAGTGTCCACCATGCTGGAACCGTCTCGCCCAGCGCTACCTGATCTGGGAGTGCTGC
CCGCTGTGGATGTCCATCAAGCAGGGAGTGAAGTTGGTGGTCATGGACCCGTTTACTGAC
CTCACCATCACTATGTGCATCGTACTCAACACACTCTTCATGGCGCTGGAGCACTACAAC
ATGACAAGTGAATTCGAGGAGATGCTGCAGGTCGGAAACCTGGTCTTCACAGGGATTTTC
ACAGCAGAGATGACCTTCAAGATCATTGCCCTCGACCCCTACTACTACTTCCAACAGGGC
TGGAACATCTTCGACAGCATCATCGTCATCCTTAGCCTCATGGAGCTGGGCCTGTCCCGC
ATGAGCAACTTGTCGGTGCTGCGCTCCTTCCGCCTGCTGCGGGTCTTCAAGCTGGCCAAA
TCATGGCCCACCCTGAACACACTCATCAAGATCATCGGGAACTCAGTGGGGGCACTGGGG
AACCTGACACTGGTGCTAGCCATCATCGTGTTCATCTTTGCTGTGGTGGGCATGCAGCTC
TTTGGCAAGAACTACTCGGAGCTGAGGGACAGCGACTCAGGCCTGCTGCCTCGCTGGCAC
ATGATGGACTTCTTTCATGCCTTCCTCATCATCTTCCGCATCCTCTGTGGAGAGTGGATC
GAGACCATGTGGGACTGCATGGAGGTGTCGGGGCAGTCATTATGCCTGCTGGTCTTCTTG
CTTGTTATGGTCATTGGCAACCTTGTGGTCCTGAATCTCTTCCTGGCCTTGCTGCTCAGC
TCCTTCAGTGCAGACAACCTCACAGCCCCTGATGAGGACAGAGAGATGAACAACCTCCAG
CTGGCCCTGGCCCGCATCCAGAGGGGCCTGCGCTTTGTCAAGCGGACCACCTGGGATTTC
TGCTGTGGTCTCCTGCGGCACCGGCCTCAGAAGCCCGCAGCCCTTGCCGCCCAGGGCCAG
CTGCCCAGCTGCATTGCCACCCCCTACTCCCCGCCACCCCCAGAGACGGAGAAGGTGCCT
CCCACCCGCAAGGAAACACGGTTTGAGGAAGGCGAGCAACCAGGCCAGGGCACCCCCGGG
GATCCAGAGCCCGTGTGTGTGCCCATCGCTGTGGCCGAGTCAGACACAGATGACCAAGAA
GAGGATGAGGAGAACAGCCTGGGCACGGAGGAGGAGTCCAGCAAGCAGCAGGAATCCCAG
CCTGTGTCCGGCTGGCCCAGAGGCCCTCCGGATTCCAGGACCTGGAGCCAGGTGTCAGCG
ACTGCCTCCTCTGAGGCCGAGGCCAGTGCATCTCAGGCCGACTGGCGGCAGCAGTGGAAA
GCGGAACCCCAGGCCCCAGGGTGCGGTGAGACCCCAGAGGACAGTTGCTCCGAGGGCAGC
ACAGCAGACATGACCAACACCGCTGAGCTCCTGGAGCAGATCCCTGACCTCGGCCAGGAT
GTCAAGGACCCAGAGGACTGCTTCACTGAAGGCTGTGTCCGGCGCTGTCCCTGCTGTGCG
GTGGACACCACACAGGCCCCAGGGAAGGTCTGGTGGCGGTTGCGCAAGACCTGCTACCAC
ATCGTGGAGCACAGCTGGTTCGAGACATTCATCATCTTCATGATCCTACTCAGCAGTGGA
GCGCTGGCCTTCGAGGACATCTACCTAGAGGAGCGGAAGACCATCAAGGTTCTGCTTGAG
TATGCCGACAAGATGTTCACATATGTCTTCGTGCTGGAGATGCTGCTCAAGTGGGTGGCC
TACGGCTTCAAGAAGTACTTCACCAATGCCTGGTGCTGGCTCGACTTCCTCATCGTAGAC
GTCTCTCTGGTCAGCCTGGTGGCCAACACCCTGGGCTTTGCCGAGATGGGCCCCATCAAG
TCACTGCGGACGCTGCGTGCACTCCGTCCTCTGAGAGCTCTGTCACGATTTGAGGGCATG
AGGGTGGTGGTCAATGCCCTGGTGGGCGCCATCCCGTCCATCATGAACGTCCTCCTCGTC
TGCCTCATCTTCTGGCTCATCTTCAGCATCATGGGCGTGAACCTCTTTGCGGGGAAGTTT
GGGAGGTGCATCAACCAGACAGAGGGAGACTTGCCTTTGAACTACACCATCGTGAACAAC
AAGAGCCAGTGTGAGTCCTTGAACTTGACCGGAGAATTGTACTGGACCAAGGTGAAAGTC
AACTTTGACAACGTGGGGGCCGGGTACCTGGCCCTTCTGCAGGTGGCAACATTTAAAGGC
TGGATGGACATTATGTATGCAGCTGTGGACTCCAGGGGGTATGAAGAGCAGCCTCAGTGG
GAATACAACCTCTACATGTACATCTATTTTGTCATTTTCATCATCTTTGGGTCTTTCTTC
ACCCTGAACCTCTTTATTGGTGTCATCATTGACAACTTCAACCAACAGAAGAAAACGTTA
GGGGGCCAGGACATCTTCATGACAGAGGAGCAGAAGAAGTACTACAATGCCACGAAGAAG
CTGGGCTCCAAGAAGCCCCAGAAGCCCATCCCACGGCCCCTGAACAAGTACCAGGGCTTC
ATATTCGACATTGTGACCAAGCAGGCCTTTGACGTCACCATCATGTTTCTGATCTGCTTG
AATATGGTGACCATGATGGTGGAGACAGATGACCAAAGTCCTGAGAAAATCAACATCTTG
GCCAAGATCAACCTGCTCTTTGTGGCCATCTTCACAGGCGAGTGTATTGTCAAGCTGGCT
GCCCTGCGCCACTACTACTTCACCAACAGCTGGAATATCTTCGACTTCGTGGTTGTCATC
CTCTCCATCGTGGGCACTGTGCTCTCGGACATCATCCAGAAGTACTTCTTCTCCCCGACG
CTCTTCCGAGTCATCCGCCTGGCCCGAATAGGCCGCATCCTCAGACTGATCCGAGGGGCC
AAGGGGATCCGCACGCTGCTCTTTGCCCTCATGATGTCCCTGCCTGCCCTCTTCAACATC
GGGCTGCTGCTCTTCCTCGTCATGTTCATCTACTCCATCTTTGGCATGGCCAACTTCGCT
TATGTCAAGTGGGAGGCTGGCATCGACGACATGTTCAACTTCCAGACCTTCGCCAACAGC
ATGCTGTGCCTCTTCCAGATCACCACGTCGGCCGGCTGGGATGGCCTCCTCAGCCCCATC
CTCAACACTGGGCCGCCCTACTGCGACCCCACTCTGCCCAACAGCAATGGCTCTCGGGGG
GACTGCGGGAGCCCAGCCGTGGGCATCCTCTTCTTCACCACCTACATCATCATCTCCTTC
CTCATCGTGGTCAACATGTACATTGCCATCATCCTGGAGAACTTCAGCGTGGCCACGGAG
GAGAGCACCGAGCCCCTGAGTGAGGACGACTTCGATATGTTCTATGAGATCTGGGAGAAA
TTTGACCCAGAGGCCACTCAGTTTATTGAGTATTCGGTCCTGTCTGACTTTGCCGACGCC
CTGTCTGAGCCACTCCGTATCGCCAAGCCCAACCAGATAAGCCTCATCAACATGGACCTG
CCCATGGTGAGTGGGGACCGCATCCATTGCATGGACATTCTCTTTGCCTTCACCAAAAGG
GTCCTGGGGGAGTCTGGGGAGATGGACGCCCTGAAGATCCAGATGGAGGAGAAGTTCATG
GCAGCCAACCCATCCAAGATCTCCTACGAGCCCATCACCACCACACTCCGGCGCAAGCAC
GAAGAGGTGTCGGCCATGGTTATCCAGAGAGCCTTCCGCAGGCACCTGCTGCAACGCTCT
TTGAAGCATGCCTCCTTCCTCTTCCGTCAGCAGGCGGGCAGCGGCCTCTCCGAAGAGGAT
GCCCCTGAGCGAGAGGGCCTCATCGCCTACGTGATGAGTGAGAACTTCTCCCGACCCCTT
GGCCCACCCTCCAGCTCCTCCATCTCCTCCACTTCCTTCCCACCCTCCTATGACAGTGTC
ACTAGAGCCACCAGCGATAACCTCCAGGTGCGGGGGTCTGACTACAGCCACAGTGAAGAT
CTCGCCGACTTCCCCCCTTCTCCGGACAGGGACCGTGAGTCCATCGTGTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>2016</residue_number>
    <molecular_weight>226937.5</molecular_weight>
    <theoretical_pi>5.15</theoretical_pi>
    <pfams>
      <pfam>
        <name>Ion_trans</name>
        <pfam_id>PF00520</pfam_id>
      </pfam>
      <pfam>
        <name>Na_trans_assoc</name>
        <pfam_id>PF06512</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>127-150</region>
      <region>159-178</region>
      <region>192-210</region>
      <region>217-236</region>
      <region>253-276</region>
      <region>390-415</region>
      <region>712-736</region>
      <region>748-771</region>
      <region>780-799</region>
      <region>806-825</region>
      <region>842-862</region>
      <region>914-939</region>
      <region>1201-1224</region>
      <region>1238-1263</region>
      <region>1270-1291</region>
      <region>1296-1317</region>
      <region>1337-1359</region>
      <region>1444-1470</region>
      <region>1524-1547</region>
      <region>1559-1582</region>
      <region>1589-1612</region>
      <region>1623-1644</region>
      <region>1660-1682</region>
      <region>1748-1772</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;Sodium channel protein type 5 subunit alpha
MANFLLPRGTSSFRRFTRESLAAIEKRMAEKQARGSTTLQESREGLPEEEAPRPQLDLQA
SKKLPDLYGNPPQELIGEPLEDLDPFYSTQKTFIVLNKGKTIFRFSATNALYVLSPFHPI
RRAAVKILVHSLFNMLIMCTILTNCVFMAQHDPPPWTKYVEYTFTAIYTFESLVKILARG
FCLHAFTFLRDPWNWLDFSVIIMAYTTEFVDLGNVSALRTFRVLRALKTISVISGLKTIV
GALIQSVKKLADVMVLTVFCLSVFALIGLQLFMGNLRHKCVRNFTALNGTNGSVEADGLV
WESLDLYLSDPENYLLKNGTSDVLLCGNSSDAGTCPEGYRCLKAGENPDHGYTSFDSFAW
AFLALFRLMTQDCWERLYQQTLRSAGKIYMIFFMLVIFLGSFYLVNLILAVVAMAYEEQN
QATIAETEEKEKRFQEAMEMLKKEHEALTIRGVDTVSRSSLEMSPLAPVNSHERRSKRRK
RMSSGTEECGEDRLPKSDSEDGPRAMNHLSLTRGLSRTSMKPRSSRGSIFTFRRRDLGSE
ADFADDENSTAGESESHHTSLLVPWPLRRTSAQGQPSPGTSAPGHALHGKKNSTVDCNGV
VSLLGAGDPEATSPGSHLLRPVMLEHPPDTTTPSEEPGGPQMLTSQAPCVDGFEEPGARQ
RALSAVSVLTSALEELEESRHKCPPCWNRLAQRYLIWECCPLWMSIKQGVKLVVMDPFTD
LTITMCIVLNTLFMALEHYNMTSEFEEMLQVGNLVFTGIFTAEMTFKIIALDPYYYFQQG
WNIFDSIIVILSLMELGLSRMSNLSVLRSFRLLRVFKLAKSWPTLNTLIKIIGNSVGALG
NLTLVLAIIVFIFAVVGMQLFGKNYSELRDSDSGLLPRWHMMDFFHAFLIIFRILCGEWI
ETMWDCMEVSGQSLCLLVFLLVMVIGNLVVLNLFLALLLSSFSADNLTAPDEDREMNNLQ
LALARIQRGLRFVKRTTWDFCCGLLRQRPQKPAALAAQGQLPSCIATPYSPPPPETEKVP
PTRKETRFEEGEQPGQGTPGDPEPVCVPIAVAESDTDDQEEDEENSLGTEEESSKQQESQ
PVSGGPEAPPDSRTWSQVSATASSEAEASASQADWRQQWKAEPQAPGCGETPEDSCSEGS
TADMTNTAELLEQIPDLGQDVKDPEDCFTEGCVRRCPCCAVDTTQAPGKVWWRLRKTCYH
IVEHSWFETFIIFMILLSSGALAFEDIYLEERKTIKVLLEYADKMFTYVFVLEMLLKWVA
YGFKKYFTNAWCWLDFLIVDVSLVSLVANTLGFAEMGPIKSLRTLRALRPLRALSRFEGM
RVVVNALVGAIPSIMNVLLVCLIFWLIFSIMGVNLFAGKFGRCINQTEGDLPLNYTIVNN
KSQCESLNLTGELYWTKVKVNFDNVGAGYLALLQVATFKGWMDIMYAAVDSRGYEEQPQW
EYNLYMYIYFVIFIIFGSFFTLNLFIGVIIDNFNQQKKKLGGQDIFMTEEQKKYYNAMKK
LGSKKPQKPIPRPLNKYQGFIFDIVTKQAFDVTIMFLICLNMVTMMVETDDQSPEKINIL
AKINLLFVAIFTGECIVKLAALRHYYFTNSWNIFDFVVVILSIVGTVLSDIIQKYFFSPT
LFRVIRLARIGRILRLIRGAKGIRTLLFALMMSLPALFNIGLLLFLVMFIYSIFGMANFA
YVKWEAGIDDMFNFQTFANSMLCLFQITTSAGWDGLLSPILNTGPPYCDPTLPNSNGSRG
DCGSPAVGILFFTTYIIISFLIVVNMYIAIILENFSVATEESTEPLSEDDFDMFYEIWEK
FDPEATQFIEYSVLSDFADALSEPLRIAKPNQISLINMDLPMVSGDRIHCMDILFAFTKR
VLGESGEMDALKIQMEEKFMAANPSKISYEPITTTLRRKHEEVSAMVIQRAFRRHLLQRS
LKHASFLFRQQAGSGLSEEDAPEREGLIAYVMSENFSRPLGPPSSSSISSTSFPPSYDSV
TRATSDNLQVRGSDYSHSEDLADFPPSPDRDRESIV</protein_sequence>
  </protein_properties>
  <genbank_protein_id>44886082</genbank_protein_id>
  <uniprot_id>Q14524</uniprot_id>
  <uniprot_name>SCN5A_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>AB158469</genbank_gene_id>
  <genecard_id>SCN5A</genecard_id>
  <geneatlas_id>SCN5A</geneatlas_id>
  <hgnc_id>HGNC:10593</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Gellens ME, George AL Jr, Chen LQ, Chahine M, Horn R, Barchi RL, Kallen RG: Primary structure and functional expression of the human cardiac tetrodotoxin-insensitive voltage-dependent sodium channel. Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):554-8.</reference_text>
      <pubmed_id>1309946</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ou Y, Gibbons SJ, Miller SM, Strege PR, Rich A, Distad MA, Ackerman MJ, Rae JL, Szurszewski JH, Farrugia G: SCN5A is expressed in human jejunal circular smooth muscle cells.  Neurogastroenterol Motil. 2002 Oct;14(5):477-86.</reference_text>
      <pubmed_id>12358675</pubmed_id>
    </reference>
    <reference>
      <reference_text>Makielski JC, Ye B, Valdivia CR, Pagel MD, Pu J, Tester DJ, Ackerman MJ: A ubiquitous splice variant and a common polymorphism affect heterologous expression of recombinant human SCN5A heart sodium channels. Circ Res. 2003 Oct 31;93(9):821-8. Epub 2003 Sep 18.</reference_text>
      <pubmed_id>14500339</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ye B, Valdivia CR, Ackerman MJ, Makielski JC: A common human SCN5A polymorphism modifies expression of an arrhythmia causing mutation. Physiol Genomics. 2003 Feb 6;12(3):187-93.</reference_text>
      <pubmed_id>12454206</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ou SW, Kameyama A, Hao LY, Horiuchi M, Minobe E, Wang WY, Makita N, Kameyama M: Tetrodotoxin-resistant Na+ channels in human neuroblastoma cells are encoded by new variants of Nav1.5/SCN5A. Eur J Neurosci. 2005 Aug;22(4):793-801.</reference_text>
      <pubmed_id>16115203</pubmed_id>
    </reference>
    <reference>
      <reference_text>Muzny DM, Scherer SE, Kaul R, Wang J, Yu J, Sudbrak R, Buhay CJ, Chen R, Cree A, Ding Y, Dugan-Rocha S, Gill R, Gunaratne P, Harris RA, Hawes AC, Hernandez J, Hodgson AV, Hume J, Jackson A, Khan ZM, Kovar-Smith C, Lewis LR, Lozado RJ, Metzker ML, Milosavljevic A, Miner GR, Morgan MB, Nazareth LV, Scott G, Sodergren E, Song XZ, Steffen D, Wei S, Wheeler DA, Wright MW, Worley KC, Yuan Y, Zhang Z, Adams CQ, Ansari-Lari MA, Ayele M, Brown MJ, Chen G, Chen Z, Clendenning J, Clerc-Blankenburg KP, Chen R, Chen Z, Davis C, Delgado O, Dinh HH, Dong W, Draper H, Ernst S, Fu G, Gonzalez-Garay ML, Garcia DK, Gillett W, Gu J, Hao B, Haugen E, Havlak P, He X, Hennig S, Hu S, Huang W, Jackson LR, Jacob LS, Kelly SH, Kube M, Levy R, Li Z, Liu B, Liu J, Liu W, Lu J, Maheshwari M, Nguyen BV, Okwuonu GO, Palmeiri A, Pasternak S, Perez LM, Phelps KA, Plopper FJ, Qiang B, Raymond C, Rodriguez R, Saenphimmachak C, Santibanez J, Shen H, Shen Y, Subramanian S, Tabor PE, Verduzco D, Waldron L, Wang J, Wang J, Wang Q, Williams GA, Wong GK, Yao Z, Zhang J, Zhang X, Zhao G, Zhou J, Zhou Y, Nelson D, Lehrach H, Reinhardt R, Naylor SL, Yang H, Olson M, Weinstock G, Gibbs RA: The DNA sequence, annotation and analysis of human chromosome 3.  Nature. 2006 Apr 27;440(7088):1194-8.</reference_text>
      <pubmed_id>16641997</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>van Bemmelen MX, Rougier JS, Gavillet B, Apotheloz F, Daidie D, Tateyama M, Rivolta I, Thomas MA, Kass RS, Staub O, Abriel H: Cardiac voltage-gated sodium channel Nav1.5 is regulated by Nedd4-2 mediated ubiquitination. Circ Res. 2004 Aug 6;95(3):284-91. Epub 2004 Jun 24.</reference_text>
      <pubmed_id>15217910</pubmed_id>
    </reference>
    <reference>
      <reference_text>Rougier JS, van Bemmelen MX, Bruce MC, Jespersen T, Gavillet B, Apotheloz F, Cordonier S, Staub O, Rotin D, Abriel H: Molecular determinants of voltage-gated sodium channel regulation by the Nedd4/Nedd4-like proteins. Am J Physiol Cell Physiol. 2005 Mar;288(3):C692-701. Epub 2004 Nov 17.</reference_text>
      <pubmed_id>15548568</pubmed_id>
    </reference>
    <reference>
      <reference_text>Dichgans M, Freilinger T, Eckstein G, Babini E, Lorenz-Depiereux B, Biskup S, Ferrari MD, Herzog J, van den Maagdenberg AM, Pusch M, Strom TM: Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet. 2005 Jul 30-Aug 5;366(9483):371-7.</reference_text>
      <pubmed_id>16054936</pubmed_id>
    </reference>
    <reference>
      <reference_text>Valdivia CR, Ueda K, Ackerman MJ, Makielski JC: GPD1L links redox state to cardiac excitability by PKC-dependent phosphorylation of the sodium channel SCN5A. Am J Physiol Heart Circ Physiol. 2009 Oct;297(4):H1446-52. Epub 2009 Aug       7.</reference_text>
      <pubmed_id>19666841</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wang J, Ou SW, Wang YJ, Kameyama M, Kameyama A, Zong ZH: Analysis of four novel variants of Nav1.5/SCN5A cloned from the brain.  Neurosci Res. 2009 Aug;64(4):339-47. Epub 2009 Apr 17.</reference_text>
      <pubmed_id>19376164</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zimmer T, Surber R: SCN5A channelopathies--an update on mutations and mechanisms.  Prog Biophys Mol Biol. 2008 Oct-Nov;98(2-3):120-36. Epub 2008 Nov 5.</reference_text>
      <pubmed_id>19027780</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL, Moss AJ, Towbin JA, Keating MT: SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 1995 Mar 10;80(5):805-11.</reference_text>
      <pubmed_id>7889574</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wang Q, Shen J, Li Z, Timothy K, Vincent GM, Priori SG, Schwartz PJ, Keating MT: Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Hum Mol Genet. 1995 Sep;4(9):1603-7.</reference_text>
      <pubmed_id>8541846</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bennett PB, Yazawa K, Makita N, George AL Jr: Molecular mechanism for an inherited cardiac arrhythmia.  Nature. 1995 Aug 24;376(6542):683-5.</reference_text>
      <pubmed_id>7651517</pubmed_id>
    </reference>
    <reference>
      <reference_text>An RH, Wang XL, Kerem B, Benhorin J, Medina A, Goldmit M, Kass RS: Novel LQT-3 mutation affects Na+ channel activity through interactions between alpha- and beta1-subunits. Circ Res. 1998 Jul 27;83(2):141-6.</reference_text>
      <pubmed_id>9686753</pubmed_id>
    </reference>
    <reference>
      <reference_text>Makita N, Shirai N, Nagashima M, Matsuoka R, Yamada Y, Tohse N, Kitabatake A: A de novo missense mutation of human cardiac Na+ channel exhibiting novel molecular mechanisms of long QT syndrome. FEBS Lett. 1998 Feb 13;423(1):5-9.</reference_text>
      <pubmed_id>9506831</pubmed_id>
    </reference>
    <reference>
      <reference_text>Benhorin J, Goldmit M, MacCluer JW, Blangero J, Goffen R, Leibovitch A, Rahat A, Wang Q, Medina A, Towbin J, Kerem B: Identification of a new SCN5A mutation, D1840G, associated with the long QT syndrome. Mutations in brief no. 153. Online. Hum Mutat. 1998;12(1):72.</reference_text>
      <pubmed_id>10627139</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, Potenza D, Moya A, Borggrefe M, Breithardt G, Ortiz-Lopez R, Wang Z, Antzelevitch C, O'Brien RE, Schulze-Bahr E, Keating MT, Towbin JA, Wang Q: Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature. 1998 Mar 19;392(6673):293-6.</reference_text>
      <pubmed_id>9521325</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wattanasirichaigoon D, Vesely MR, Duggal P, Levine JC, Blume ED, Wolff GS, Edwards SB, Beggs AH: Sodium channel abnormalities are infrequent in patients with long QT syndrome: identification of two novel SCN5A mutations. Am J Med Genet. 1999 Oct 29;86(5):470-6.</reference_text>
      <pubmed_id>10508990</pubmed_id>
    </reference>
    <reference>
      <reference_text>Rook MB, Bezzina Alshinawi C, Groenewegen WA, van Gelder IC, van Ginneken AC, Jongsma HJ, Mannens MM, Wilde AA: Human SCN5A gene mutations alter cardiac sodium channel kinetics and are associated with the Brugada syndrome. Cardiovasc Res. 1999 Dec;44(3):507-17.</reference_text>
      <pubmed_id>10690282</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wei J, Wang DW, Alings M, Fish F, Wathen M, Roden DM, George AL Jr: Congenital long-QT syndrome caused by a novel mutation in a conserved acidic domain of the cardiac Na+ channel. Circulation. 1999 Jun 22;99(24):3165-71.</reference_text>
      <pubmed_id>10377081</pubmed_id>
    </reference>
    <reference>
      <reference_text>Dumaine R, Towbin JA, Brugada P, Vatta M, Nesterenko DV, Nesterenko VV, Brugada J, Brugada R, Antzelevitch C: Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. Circ Res. 1999 Oct 29;85(9):803-9.</reference_text>
      <pubmed_id>10532948</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bezzina C, Veldkamp MW, van Den Berg MP, Postma AV, Rook MB, Viersma JW, van Langen IM, Tan-Sindhunata G, Bink-Boelkens MT, van Der Hout AH, Mannens MM, Wilde AA: A single Na(+) channel mutation causing both long-QT and Brugada syndromes. Circ Res. 1999 Dec 3-17;85(12):1206-13.</reference_text>
      <pubmed_id>10590249</pubmed_id>
    </reference>
    <reference>
      <reference_text>Schott JJ, Alshinawi C, Kyndt F, Probst V, Hoorntje TM, Hulsbeek M, Wilde AA, Escande D, Mannens MM, Le Marec H: Cardiac conduction defects associate with mutations in SCN5A.  Nat Genet. 1999 Sep;23(1):20-1.</reference_text>
      <pubmed_id>10471492</pubmed_id>
    </reference>
    <reference>
      <reference_text>Makita N, Shirai N, Wang DW, Sasaki K, George AL Jr, Kanno M, Kitabatake A: Cardiac Na(+) channel dysfunction in Brugada syndrome is aggravated by beta(1)-subunit. Circulation. 2000 Jan 4-11;101(1):54-60.</reference_text>
      <pubmed_id>10618304</pubmed_id>
    </reference>
    <reference>
      <reference_text>Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, Moss AJ, Schwartz PJ, Towbin JA, Vincent GM, Keating MT: Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation. 2000 Sep 5;102(10):1178-85.</reference_text>
      <pubmed_id>10973849</pubmed_id>
    </reference>
    <reference>
      <reference_text>Akai J, Makita N, Sakurada H, Shirai N, Ueda K, Kitabatake A, Nakazawa K, Kimura A, Hiraoka M: A novel SCN5A mutation associated with idiopathic ventricular fibrillation without typical ECG findings of Brugada syndrome. FEBS Lett. 2000 Aug 11;479(1-2):29-34.</reference_text>
      <pubmed_id>10940383</pubmed_id>
    </reference>
    <reference>
      <reference_text>Schwartz PJ, Priori SG, Dumaine R, Napolitano C, Antzelevitch C, Stramba-Badiale M, Richard TA, Berti MR, Bloise R: A molecular link between the sudden infant death syndrome and the long-QT syndrome. N Engl J Med. 2000 Jul 27;343(4):262-7.</reference_text>
      <pubmed_id>10911008</pubmed_id>
    </reference>
    <reference>
      <reference_text>Abriel H, Cabo C, Wehrens XH, Rivolta I, Motoike HK, Memmi M, Napolitano C, Priori SG, Kass RS: Novel arrhythmogenic mechanism revealed by a long-QT syndrome mutation in the cardiac Na(+) channel. Circ Res. 2001 Apr 13;88(7):740-5.</reference_text>
      <pubmed_id>11304498</pubmed_id>
    </reference>
    <reference>
      <reference_text>Rivolta I, Abriel H, Tateyama M, Liu H, Memmi M, Vardas P, Napolitano C, Priori SG, Kass RS: Inherited Brugada and long QT-3 syndrome mutations of a single residue of the cardiac sodium channel confer distinct channel and clinical phenotypes. J Biol Chem. 2001 Aug 17;276(33):30623-30. Epub 2001 Jun 15.</reference_text>
      <pubmed_id>11410597</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kyndt F, Probst V, Potet F, Demolombe S, Chevallier JC, Baro I, Moisan JP, Boisseau P, Schott JJ, Escande D, Le Marec H: Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation. 2001 Dec 18;104(25):3081-6.</reference_text>
      <pubmed_id>11748104</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ackerman MJ, Siu BL, Sturner WQ, Tester DJ, Valdivia CR, Makielski JC, Towbin JA: Postmortem molecular analysis of SCN5A defects in sudden infant death syndrome. JAMA. 2001 Nov 14;286(18):2264-9.</reference_text>
      <pubmed_id>11710892</pubmed_id>
    </reference>
    <reference>
      <reference_text>Tan HL, Bink-Boelkens MT, Bezzina CR, Viswanathan PC, Beaufort-Krol GC, van Tintelen PJ, van den Berg MP, Wilde AA, Balser JR: A sodium-channel mutation causes isolated cardiac conduction disease.  Nature. 2001 Feb 22;409(6823):1043-7.</reference_text>
      <pubmed_id>11234013</pubmed_id>
    </reference>
    <reference>
      <reference_text>Smits JP, Eckardt L, Probst V, Bezzina CR, Schott JJ, Remme CA, Haverkamp W, Breithardt G, Escande D, Schulze-Bahr E, LeMarec H, Wilde AA: Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients. J Am Coll Cardiol. 2002 Jul 17;40(2):350-6.</reference_text>
      <pubmed_id>12106943</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wang DW, Viswanathan PC, Balser JR, George AL Jr, Benson DW: Clinical, genetic, and biophysical characterization of SCN5A mutations associated with atrioventricular conduction block. Circulation. 2002 Jan 22;105(3):341-6.</reference_text>
      <pubmed_id>11804990</pubmed_id>
    </reference>
    <reference>
      <reference_text>Clancy CE, Rudy Y: Na(+) channel mutation that causes both Brugada and long-QT syndrome phenotypes: a simulation study of mechanism. Circulation. 2002 Mar 12;105(10):1208-13.</reference_text>
      <pubmed_id>11889015</pubmed_id>
    </reference>
    <reference>
      <reference_text>Priori SG, Napolitano C, Gasparini M, Pappone C, Della Bella P, Giordano U, Bloise R, Giustetto C, De Nardis R, Grillo M, Ronchetti E, Faggiano G, Nastoli J: Natural history of Brugada syndrome: insights for risk stratification and management. Circulation. 2002 Mar 19;105(11):1342-7.</reference_text>
      <pubmed_id>11901046</pubmed_id>
    </reference>
    <reference>
      <reference_text>Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, Hohnloser SH, Shimizu W, Schwartz PJ, Stanton M, Murray KT, Norris K, George AL Jr, Roden DM: Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation. 2002 Apr 23;105(16):1943-8.</reference_text>
      <pubmed_id>11997281</pubmed_id>
    </reference>
    <reference>
      <reference_text>Vatta M, Dumaine R, Varghese G, Richard TA, Shimizu W, Aihara N, Nademanee K, Brugada R, Brugada J, Veerakul G, Li H, Bowles NE, Brugada P, Antzelevitch C, Towbin JA: Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet. 2002 Feb 1;11(3):337-45.</reference_text>
      <pubmed_id>11823453</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chen S, Chung MK, Martin D, Rozich R, Tchou PJ, Wang Q: SNP S1103Y in the cardiac sodium channel gene SCN5A is associated with cardiac arrhythmias and sudden death in a white family. J Med Genet. 2002 Dec;39(12):913-5.</reference_text>
      <pubmed_id>12471205</pubmed_id>
    </reference>
    <reference>
      <reference_text>Vatta M, Dumaine R, Antzelevitch C, Brugada R, Li H, Bowles NE, Nademanee K, Brugada J, Brugada P, Towbin JA: Novel mutations in domain I of SCN5A cause Brugada syndrome.  Mol Genet Metab. 2002 Apr;75(4):317-24.</reference_text>
      <pubmed_id>12051963</pubmed_id>
    </reference>
    <reference>
      <reference_text>Rivolta I, Clancy CE, Tateyama M, Liu H, Priori SG, Kass RS: A novel SCN5A mutation associated with long QT-3: altered inactivation kinetics and channel dysfunction. Physiol Genomics. 2002 Sep 3;10(3):191-7.</reference_text>
      <pubmed_id>12209021</pubmed_id>
    </reference>
    <reference>
      <reference_text>Splawski I, Timothy KW, Tateyama M, Clancy CE, Malhotra A, Beggs AH, Cappuccio FP, Sagnella GA, Kass RS, Keating MT: Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia.  Science. 2002 Aug 23;297(5585):1333-6.</reference_text>
      <pubmed_id>12193783</pubmed_id>
    </reference>
    <reference>
      <reference_text>Groenewegen WA, Firouzi M, Bezzina CR, Vliex S, van Langen IM, Sandkuijl L, Smits JP, Hulsbeek M, Rook MB, Jongsma HJ, Wilde AA: A cardiac sodium channel mutation cosegregates with a rare connexin40 genotype in familial atrial standstill. Circ Res. 2003 Jan 10;92(1):14-22.</reference_text>
      <pubmed_id>12522116</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bezzina CR, Rook MB, Groenewegen WA, Herfst LJ, van der Wal AC, Lam J, Jongsma HJ, Wilde AA, Mannens MM: Compound heterozygosity for mutations (W156X and R225W) in SCN5A associated with severe cardiac conduction disturbances and degenerative changes in the conduction system. Circ Res. 2003 Feb 7;92(2):159-68.</reference_text>
      <pubmed_id>12574143</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wehrens XH, Rossenbacker T, Jongbloed RJ, Gewillig M, Heidbuchel H, Doevendans PA, Vos MA, Wellens HJ, Kass RS: A novel mutation L619F in the cardiac Na+ channel SCN5A associated with long-QT syndrome (LQT3): a role for the I-II linker in inactivation gating. Hum Mutat. 2003 May;21(5):552.</reference_text>
      <pubmed_id>12673799</pubmed_id>
    </reference>
    <reference>
      <reference_text>Viswanathan PC, Benson DW, Balser JR: A common SCN5A polymorphism modulates the biophysical effects of an SCN5A mutation. J Clin Invest. 2003 Feb;111(3):341-6.</reference_text>
      <pubmed_id>12569159</pubmed_id>
    </reference>
    <reference>
      <reference_text>Benson DW, Wang DW, Dyment M, Knilans TK, Fish FA, Strieper MJ, Rhodes TH, George AL Jr: Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). J Clin Invest. 2003 Oct;112(7):1019-28.</reference_text>
      <pubmed_id>14523039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Valdivia CR, Tester DJ, Rok BA, Porter CB, Munger TM, Jahangir A, Makielski JC, Ackerman MJ: A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs. Cardiovasc Res. 2004 Apr 1;62(1):53-62.</reference_text>
      <pubmed_id>15023552</pubmed_id>
    </reference>
    <reference>
      <reference_text>McNair WP, Ku L, Taylor MR, Fain PR, Dao D, Wolfel E, Mestroni L: SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia. Circulation. 2004 Oct 12;110(15):2163-7. Epub 2004 Oct 4.</reference_text>
      <pubmed_id>15466643</pubmed_id>
    </reference>
    <reference>
      <reference_text>Shin DJ, Jang Y, Park HY, Lee JE, Yang K, Kim E, Bae Y, Kim J, Kim J, Kim SS, Lee MH, Chahine M, Yoon SK: Genetic analysis of the cardiac sodium channel gene SCN5A in Koreans with Brugada syndrome. J Hum Genet. 2004;49(10):573-8. Epub 2004 Aug 26.</reference_text>
      <pubmed_id>15338453</pubmed_id>
    </reference>
    <reference>
      <reference_text>Mohler PJ, Rivolta I, Napolitano C, LeMaillet G, Lambert S, Priori SG, Bennett V: Nav1.5 E1053K mutation causing Brugada syndrome blocks binding to ankyrin-G and expression of Nav1.5 on the surface of cardiomyocytes. Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17533-8. Epub 2004 Dec 3.</reference_text>
      <pubmed_id>15579534</pubmed_id>
    </reference>
    <reference>
      <reference_text>Amin AS, Verkerk AO, Bhuiyan ZA, Wilde AA, Tan HL: Novel Brugada syndrome-causing mutation in ion-conducting pore of cardiac Na+ channel does not affect ion selectivity properties. Acta Physiol Scand. 2005 Dec;185(4):291-301.</reference_text>
      <pubmed_id>16266370</pubmed_id>
    </reference>
    <reference>
      <reference_text>Yokoi H, Makita N, Sasaki K, Takagi Y, Okumura Y, Nishino T, Makiyama T, Kitabatake A, Horie M, Watanabe I, Tsutsui H: Double SCN5A mutation underlying asymptomatic Brugada syndrome.  Heart Rhythm. 2005 Mar;2(3):285-92.</reference_text>
      <pubmed_id>15851320</pubmed_id>
    </reference>
    <reference>
      <reference_text>Makiyama T, Akao M, Tsuji K, Doi T, Ohno S, Takenaka K, Kobori A, Ninomiya T, Yoshida H, Takano M, Makita N, Yanagisawa F, Higashi Y, Takeyama Y, Kita T, Horie M: High risk for bradyarrhythmic complications in patients with Brugada syndrome caused by SCN5A gene mutations. J Am Coll Cardiol. 2005 Dec 6;46(11):2100-6. Epub 2005 Nov 4.</reference_text>
      <pubmed_id>16325048</pubmed_id>
    </reference>
    <reference>
      <reference_text>Keller DI, Huang H, Zhao J, Frank R, Suarez V, Delacretaz E, Brink M, Osswald S, Schwick N, Chahine M: A novel SCN5A mutation, F1344S, identified in a patient with Brugada syndrome and fever-induced ventricular fibrillation. Cardiovasc Res. 2006 Jun 1;70(3):521-9. Epub 2006 Mar 3.</reference_text>
      <pubmed_id>16616735</pubmed_id>
    </reference>
    <reference>
      <reference_text>Millat G, Chevalier P, Restier-Miron L, Da Costa A, Bouvagnet P, Kugener B, Fayol L, Gonzalez Armengod C, Oddou B, Chanavat V, Froidefond E, Perraudin R, Rousson R, Rodriguez-Lafrasse C: Spectrum of pathogenic mutations and associated polymorphisms in a cohort of 44 unrelated patients with long QT syndrome. Clin Genet. 2006 Sep;70(3):214-27.</reference_text>
      <pubmed_id>16922724</pubmed_id>
    </reference>
    <reference>
      <reference_text>Liang P, Liu WL, Hu DY, Li CL, Tao WH, Li L: [Novel SCN5A gene mutations associated with Brugada syndrome: V95I, A1649V and delF1617] Zhonghua Xin Xue Guan Bing Za Zhi. 2006 Jul;34(7):616-9.</reference_text>
      <pubmed_id>17081365</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bankston JR, Sampson KJ, Kateriya S, Glaaser IW, Malito DL, Chung WK, Kass RS: A novel LQT-3 mutation disrupts an inactivation gate complex with distinct rate-dependent phenotypic consequences. Channels (Austin). 2007 Jul-Aug;1(4):273-80. Epub 2007 Aug 31.</reference_text>
      <pubmed_id>18708744</pubmed_id>
    </reference>
    <reference>
      <reference_text>Pfahnl AE, Viswanathan PC, Weiss R, Shang LL, Sanyal S, Shusterman V, Kornblit C, London B, Dudley SC Jr: A sodium channel pore mutation causing Brugada syndrome.  Heart Rhythm. 2007 Jan;4(1):46-53. Epub 2006 Sep 28.</reference_text>
      <pubmed_id>17198989</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bankston JR, Yue M, Chung W, Spyres M, Pass RH, Silver E, Sampson KJ, Kass RS: A novel and lethal de novo LQT-3 mutation in a newborn with distinct molecular pharmacology and therapeutic response. PLoS One. 2007 Dec 5;2(12):e1258.</reference_text>
      <pubmed_id>18060054</pubmed_id>
    </reference>
    <reference>
      <reference_text>Tian L, Zhu JF, Yang JG: [Gene (SCN5A) mutation analysis of a Chinese family with Brugada syndrome]  Zhonghua Xin Xue Guan Bing Za Zhi. 2007 Dec;35(12):1122-5.</reference_text>
      <pubmed_id>18341814</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zhang Y, Wang T, Ma A, Zhou X, Gui J, Wan H, Shi R, Huang C, Grace AA, Huang CL, Trump D, Zhang H, Zimmer T, Lei M: Correlations between clinical and physiological consequences of the novel mutation R878C in a highly conserved pore residue in the cardiac Na+ channel. Acta Physiol (Oxf). 2008 Dec;194(4):311-23. Epub 2008 Jul 24.</reference_text>
      <pubmed_id>18616619</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bebarova M, O'Hara T, Geelen JL, Jongbloed RJ, Timmermans C, Arens YH, Rodriguez LM, Rudy Y, Volders PG: Subepicardial phase 0 block and discontinuous transmural conduction underlie right precordial ST-segment elevation by a SCN5A loss-of-function mutation. Am J Physiol Heart Circ Physiol. 2008 Jul;295(1):H48-58. Epub 2008 May 2.</reference_text>
      <pubmed_id>18456723</pubmed_id>
    </reference>
    <reference>
      <reference_text>Petitprez S, Jespersen T, Pruvot E, Keller DI, Corbaz C, Schlapfer J, Abriel H, Kucera JP: Analyses of a novel SCN5A mutation (C1850S): conduction vs. repolarization disorder hypotheses in the Brugada syndrome. Cardiovasc Res. 2008 Jun 1;78(3):494-504. Epub 2008 Feb 5.</reference_text>
      <pubmed_id>18252757</pubmed_id>
    </reference>
    <reference>
      <reference_text>Barajas-Martinez HM, Hu D, Cordeiro JM, Wu Y, Kovacs RJ, Meltser H, Kui H, Elena B, Brugada R, Antzelevitch C, Dumaine R: Lidocaine-induced Brugada syndrome phenotype linked to a novel double mutation in the cardiac sodium channel. Circ Res. 2008 Aug 15;103(4):396-404. Epub 2008 Jul 3.</reference_text>
      <pubmed_id>18599870</pubmed_id>
    </reference>
    <reference>
      <reference_text>Darbar D, Kannankeril PJ, Donahue BS, Kucera G, Stubblefield T, Haines JL, George AL Jr, Roden DM: Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. Circulation. 2008 Apr 15;117(15):1927-35. Epub 2008 Mar 31.</reference_text>
      <pubmed_id>18378609</pubmed_id>
    </reference>
    <reference>
      <reference_text>Benito B, Brugada R, Perich RM, Lizotte E, Cinca J, Mont L, Berruezo A, Tolosana JM, Freixa X, Brugada P, Brugada J: A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation. Heart Rhythm. 2008 Oct;5(10):1434-40. Epub 2008 Jul 19.</reference_text>
      <pubmed_id>18929331</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lin MT, Wu MH, Chang CC, Chiu SN, Theriault O, Huang H, Christe G, Ficker E, Chahine M: In utero onset of long QT syndrome with atrioventricular block and spontaneous or lidocaine-induced ventricular tachycardia: compound effects of hERG pore region mutation and SCN5A N-terminus variant. Heart Rhythm. 2008 Nov;5(11):1567-74. Epub 2008 Aug 17.</reference_text>
      <pubmed_id>18848812</pubmed_id>
    </reference>
    <reference>
      <reference_text>Makiyama T, Akao M, Shizuta S, Doi T, Nishiyama K, Oka Y, Ohno S, Nishio Y, Tsuji K, Itoh H, Kimura T, Kita T, Horie M: A novel SCN5A gain-of-function mutation M1875T associated with familial atrial fibrillation. J Am Coll Cardiol. 2008 Oct 14;52(16):1326-34.</reference_text>
      <pubmed_id>18929244</pubmed_id>
    </reference>
    <reference>
      <reference_text>Makita N, Behr E, Shimizu W, Horie M, Sunami A, Crotti L, Schulze-Bahr E, Fukuhara S, Mochizuki N, Makiyama T, Itoh H, Christiansen M, McKeown P, Miyamoto K, Kamakura S, Tsutsui H, Schwartz PJ, George AL Jr, Roden DM: The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. J Clin Invest. 2008 Jun;118(6):2219-29.</reference_text>
      <pubmed_id>18451998</pubmed_id>
    </reference>
    <reference>
      <reference_text>Shan L, Makita N, Xing Y, Watanabe S, Futatani T, Ye F, Saito K, Ibuki K, Watanabe K, Hirono K, Uese K, Ichida F, Miyawaki T, Origasa H, Bowles NE, Towbin JA: SCN5A variants in Japanese patients with left ventricular noncompaction and arrhythmia. Mol Genet Metab. 2008 Apr;93(4):468-74.</reference_text>
      <pubmed_id>18368697</pubmed_id>
    </reference>
    <reference>
      <reference_text>Otagiri T, Kijima K, Osawa M, Ishii K, Makita N, Matoba R, Umetsu K, Hayasaka K: Cardiac ion channel gene mutations in sudden infant death syndrome.  Pediatr Res. 2008 Nov;64(5):482-7.</reference_text>
      <pubmed_id>18596570</pubmed_id>
    </reference>
    <reference>
      <reference_text>Saito YA, Strege PR, Tester DJ, Locke GR 3rd, Talley NJ, Bernard CE, Rae JL, Makielski JC, Ackerman MJ, Farrugia G: Sodium channel mutation in irritable bowel syndrome: evidence for an ion channelopathy. Am J Physiol Gastrointest Liver Physiol. 2009 Feb;296(2):G211-8. Epub 2008       Dec 4.</reference_text>
      <pubmed_id>19056759</pubmed_id>
    </reference>
    <reference>
      <reference_text>Huang H, Millat G, Rodriguez-Lafrasse C, Rousson R, Kugener B, Chevalier P, Chahine M: Biophysical characterization of a new SCN5A mutation S1333Y in a SIDS infant linked to long QT syndrome. FEBS Lett. 2009 Mar 4;583(5):890-6. Epub 2009 Feb 10.</reference_text>
      <pubmed_id>19302788</pubmed_id>
    </reference>
    <reference>
      <reference_text>Meregalli PG, Tan HL, Probst V, Koopmann TT, Tanck MW, Bhuiyan ZA, Sacher F, Kyndt F, Schott JJ, Albuisson J, Mabo P, Bezzina CR, Le Marec H, Wilde AA: Type of SCN5A mutation determines clinical severity and degree of conduction slowing in loss-of-function sodium channelopathies. Heart Rhythm. 2009 Mar;6(3):341-8. Epub 2008 Nov 11.</reference_text>
      <pubmed_id>19251209</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hsueh CH, Chen WP, Lin JL, Tsai CT, Liu YB, Juang JM, Tsao HM, Su MJ, Lai LP: Distinct functional defect of three novel Brugada syndrome related cardiac sodium channel mutations. J Biomed Sci. 2009 Feb 20;16:23.</reference_text>
      <pubmed_id>19272188</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Indecainide</name>
        <accession>HMDB14338</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Indecainide</name>
        <accession>HMDB14338</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Indecainide</name>
        <accession>HMDB14338</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Indecainide</name>
        <accession>HMDB14338</accession>
      </metabolite>
      <reference>
        <reference_text>Jaillon P, Drici M: Recent antiarrhythmic drugs.  Am J Cardiol. 1989 Dec 5;64(20):65J-69J.</reference_text>
        <pubmed_id>2688391</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Indecainide</name>
        <accession>HMDB14338</accession>
      </metabolite>
      <reference>
        <reference_text>Holland DR, Lacefield WB, Gonzales CR, Johnston SR, Turk JA: Indecainide: effects on arrhythmias, electrophysiology, and cardiovascular dynamics. J Cardiovasc Pharmacol. 1989 Sep;14(3):454-61.</reference_text>
        <pubmed_id>2476626</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Indecainide</name>
        <accession>HMDB14338</accession>
      </metabolite>
      <reference>
        <reference_text>Steinberg MI, Wiest SA: Electrophysiological studies of indecainide hydrochloride, a new antiarrhythmic agent, in canine cardiac tissues. J Cardiovasc Pharmacol. 1984 Jul-Aug;6(4):614-21.</reference_text>
        <pubmed_id>6206315</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ranolazine</name>
        <accession>HMDB14388</accession>
      </metabolite>
      <reference>
        <reference_text>Hale SL, Kloner RA: Ranolazine, an inhibitor of the late sodium channel current, reduces postischemic myocardial dysfunction in the rabbit. J Cardiovasc Pharmacol Ther. 2006 Dec;11(4):249-55.</reference_text>
        <pubmed_id>17220471</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ranolazine</name>
        <accession>HMDB14388</accession>
      </metabolite>
      <reference>
        <reference_text>Rajamani S, Shryock JC, Belardinelli L: Block of tetrodotoxin-sensitive, Na(V)1.7 and tetrodotoxin-resistant, Na(V)1.8, Na+ channels by ranolazine. Channels (Austin). 2008 Nov-Dec;2(6):449-60. Epub 2008 Nov 7.</reference_text>
        <pubmed_id>19077543</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3',4'-Dihydrodiol</name>
        <accession>HMDB13895</accession>
      </metabolite>
      <reference>
        <reference_text>Mitiushin VM, Kozyreva EV: [Several types of mitochondrial ultrastructure in animal cell mitochondria and their relationship to energy production]. Tsitologiia. 1978 Apr;20(4):371-9.</reference_text>
        <pubmed_id>150666</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3',4'-Dihydrodiol</name>
        <accession>HMDB13895</accession>
      </metabolite>
      <reference>
        <reference_text>Swadron SP, Rudis MI, Azimian K, Beringer P, Fort D, Orlinsky M: A comparison of phenytoin-loading techniques in the emergency department.  Acad Emerg Med. 2004 Mar;11(3):244-52.</reference_text>
        <pubmed_id>15001403</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Disopyramide</name>
        <accession>HMDB14425</accession>
      </metabolite>
      <reference>
        <reference_text>Sugao M, Fujiki A, Nishida K, Sakabe M, Tsuneda T, Iwamoto J, Mizumaki K, Inoue H: Repolarization dynamics in patients with idiopathic ventricular fibrillation: pharmacological therapy with bepridil and disopyramide. J Cardiovasc Pharmacol. 2005 Jun;45(6):545-9.</reference_text>
        <pubmed_id>15897781</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Disopyramide</name>
        <accession>HMDB14425</accession>
      </metabolite>
      <reference>
        <reference_text>Fujiki A, Sugao M, Nishida K, Sakabe M, Tsuneda T, Mizumaki K, Inoue H: Repolarization abnormality in idiopathic ventricular fibrillation: assessment using 24-hour QT-RR and QaT-RR relationships. J Cardiovasc Electrophysiol. 2004 Jan;15(1):59-63.</reference_text>
        <pubmed_id>15028073</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Disopyramide</name>
        <accession>HMDB14425</accession>
      </metabolite>
      <reference>
        <reference_text>Shimizu W, Antzelevitch C, Suyama K, Kurita T, Taguchi A, Aihara N, Takaki H, Sunagawa K, Kamakura S: Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9.</reference_text>
        <pubmed_id>11196553</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Disopyramide</name>
        <accession>HMDB14425</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lidocaine</name>
        <accession>HMDB14426</accession>
      </metabolite>
      <reference>
        <reference_text>Itoh H, Tsuji K, Sakaguchi T, Nagaoka I, Oka Y, Nakazawa Y, Yao T, Jo H, Ashihara T, Ito M, Horie M, Imoto K: A paradoxical effect of lidocaine for the N406S mutation of SCN5A associated with Brugada syndrome. Int J Cardiol. 2007 Oct 18;121(3):239-48. Epub 2007 Apr 18.</reference_text>
        <pubmed_id>17445919</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lidocaine</name>
        <accession>HMDB14426</accession>
      </metabolite>
      <reference>
        <reference_text>Fedida D, Orth PM, Hesketh JC, Ezrin AM: The role of late I and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers. J Cardiovasc Electrophysiol. 2006 May;17 Suppl 1:S71-S78.</reference_text>
        <pubmed_id>16686685</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lidocaine</name>
        <accession>HMDB14426</accession>
      </metabolite>
      <reference>
        <reference_text>Wallace CH, Baczko I, Jones L, Fercho M, Light PE: Inhibition of cardiac voltage-gated sodium channels by grape polyphenols.  Br J Pharmacol. 2006 Nov;149(6):657-65. Epub 2006 Oct 3.</reference_text>
        <pubmed_id>17016511</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lidocaine</name>
        <accession>HMDB14426</accession>
      </metabolite>
      <reference>
        <reference_text>Cerne A, Bergh C, Borg K, Ek I, Gejervall AL, Hillensjo T, Olofsson JI, Stener-Victorin E, Wood M, Westlander G: Pre-ovarian block versus paracervical block for oocyte retrieval.  Hum Reprod. 2006 Nov;21(11):2916-21. Epub 2006 Jul 13.</reference_text>
        <pubmed_id>16840798</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lidocaine</name>
        <accession>HMDB14426</accession>
      </metabolite>
      <reference>
        <reference_text>Muroi Y, Chanda B: Local anesthetics disrupt energetic coupling between the voltage-sensing segments of a sodium channel. J Gen Physiol. 2009 Jan;133(1):1-15. Epub 2008 Dec 15.</reference_text>
        <pubmed_id>19088384</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lidocaine</name>
        <accession>HMDB14426</accession>
      </metabolite>
      <reference>
        <reference_text>Karoly R, Lenkey N, Juhasz AO, Vizi ES, Mike A: Fast- or slow-inactivated state preference of Na+ channel inhibitors: a simulation and experimental study. PLoS Comput Biol. 2010 Jun 17;6(6):e1000818.</reference_text>
        <pubmed_id>20585544</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mexiletine</name>
        <accession>HMDB14523</accession>
      </metabolite>
      <reference>
        <reference_text>Valdivia CR, Ackerman MJ, Tester DJ, Wada T, McCormack J, Ye B, Makielski JC: A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine. Cardiovasc Res. 2002 Aug 1;55(2):279-89.</reference_text>
        <pubmed_id>12123767</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mexiletine</name>
        <accession>HMDB14523</accession>
      </metabolite>
      <reference>
        <reference_text>Chinushi M, Tagawa M, Sugiura H, Komura S, Hosaka Y, Washizuka T, Aizawa Y: Ventricular tachyarrhythmias in a canine model of LQT3: arrhythmogenic effects of sympathetic activity and therapeutic effects of mexiletine. Circ J. 2003 Mar;67(3):263-8.</reference_text>
        <pubmed_id>12604879</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mexiletine</name>
        <accession>HMDB14523</accession>
      </metabolite>
      <reference>
        <reference_text>Fabritz L, Kirchhof P, Franz MR, Nuyens D, Rossenbacker T, Ottenhof A, Haverkamp W, Breithardt G, Carmeliet E, Carmeliet P: Effect of pacing and mexiletine on dispersion of repolarisation and arrhythmias in DeltaKPQ SCN5A (long QT3) mice. Cardiovasc Res. 2003 Mar 15;57(4):1085-93.</reference_text>
        <pubmed_id>12650887</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mexiletine</name>
        <accession>HMDB14523</accession>
      </metabolite>
      <reference>
        <reference_text>Wang HW, Zheng YQ, Yang ZF, Li CZ, Liu YM: Effect of mexiletine on long QT syndrome model.  Acta Pharmacol Sin. 2003 Apr;24(4):316-20.</reference_text>
        <pubmed_id>12676070</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mexiletine</name>
        <accession>HMDB14523</accession>
      </metabolite>
      <reference>
        <reference_text>Napolitano C, Bloise R, Priori SG: Gene-specific therapy for inherited arrhythmogenic diseases.  Pharmacol Ther. 2006 Apr;110(1):1-13. Epub 2005 Sep 15.</reference_text>
        <pubmed_id>16168489</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mexiletine</name>
        <accession>HMDB14523</accession>
      </metabolite>
      <reference>
        <reference_text>Shimizu W, Antzelevitch C, Suyama K, Kurita T, Taguchi A, Aihara N, Takaki H, Sunagawa K, Kamakura S: Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9.</reference_text>
        <pubmed_id>11196553</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mexiletine</name>
        <accession>HMDB14523</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hexylcaine</name>
        <accession>HMDB14616</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hexylcaine</name>
        <accession>HMDB14616</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hexylcaine</name>
        <accession>HMDB14616</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dibucaine</name>
        <accession>HMDB14668</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dibucaine</name>
        <accession>HMDB14668</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dibucaine</name>
        <accession>HMDB14668</accession>
      </metabolite>
      <reference>
        <reference_text>Oka M, Itoh Y, Fujita T: Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81.</reference_text>
        <pubmed_id>12354567</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dibucaine</name>
        <accession>HMDB14668</accession>
      </metabolite>
      <reference>
        <reference_text>Louro SR, Anteneodo C, Wajnberg E: Carboxyl groups at the membrane interface as molecular targets for local anesthetics. Biophys Chem. 1998 Aug 4;74(1):35-43.</reference_text>
        <pubmed_id>9742684</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dibucaine</name>
        <accession>HMDB14668</accession>
      </metabolite>
      <reference>
        <reference_text>Ryan SE, Demers CN, Chew JP, Baenziger JE: Structural effects of neutral and anionic lipids on the nicotinic acetylcholine receptor. An infrared difference spectroscopy study. J Biol Chem. 1996 Oct 4;271(40):24590-7.</reference_text>
        <pubmed_id>8798723</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dibucaine</name>
        <accession>HMDB14668</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carbamazepine</name>
        <accession>HMDB14704</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carbamazepine</name>
        <accession>HMDB14704</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carbamazepine</name>
        <accession>HMDB14704</accession>
      </metabolite>
      <reference>
        <reference_text>Yang YC, Huang CS, Kuo CC: Lidocaine, carbamazepine, and imipramine have partially overlapping binding sites and additive inhibitory effect on neuronal Na+ channels. Anesthesiology. 2010 Jul;113(1):160-74.</reference_text>
        <pubmed_id>20526191</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carbamazepine</name>
        <accession>HMDB14704</accession>
      </metabolite>
      <reference>
        <reference_text>Yang YC, Kuo CC: Inhibition of Na(+) current by imipramine and related compounds: different binding kinetics as an inactivation stabilizer and as an open channel blocker. Mol Pharmacol. 2002 Nov;62(5):1228-37.</reference_text>
        <pubmed_id>12391287</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carbamazepine</name>
        <accession>HMDB14704</accession>
      </metabolite>
      <reference>
        <reference_text>Lipkind GM, Fozzard HA: Molecular model of anticonvulsant drug binding to the voltage-gated sodium channel inner pore. Mol Pharmacol. 2010 Oct;78(4):631-8. Epub 2010 Jul 19.</reference_text>
        <pubmed_id>20643904</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Milberg P, Reinsch N, Osada N, Wasmer K, Monnig G, Stypmann J, Breithardt G, Haverkamp W, Eckardt L: Verapamil prevents torsade de pointes by reduction of transmural dispersion of repolarization and suppression of early afterdepolarizations in an intact heart model of LQT3. Basic Res Cardiol. 2005 Jul;100(4):365-71. Epub 2005 Jun 10.</reference_text>
        <pubmed_id>15944809</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Moricizine</name>
        <accession>HMDB14818</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Moricizine</name>
        <accession>HMDB14818</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Moricizine</name>
        <accession>HMDB14818</accession>
      </metabolite>
      <reference>
        <reference_text>Ahmmed GU, Hisatome I, Kurata Y, Makita N, Tanaka Y, Tanaka H, Okamura T, Sonoyama K, Furuse Y, Kato M, Yamamoto Y, Ogura K, Shimoyama M, Miake J, Sasaki N, Ogino K, Igawa O, Yoshida A, Shigemasa C: Analysis of moricizine block of sodium current in isolated guinea-pig atrial myocytes. Atrioventricular difference of moricizine block. Vascul Pharmacol. 2002 Mar;38(3):131-41.</reference_text>
        <pubmed_id>12402511</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Moricizine</name>
        <accession>HMDB14818</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Riluzole</name>
        <accession>HMDB14878</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Riluzole</name>
        <accession>HMDB14878</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Riluzole</name>
        <accession>HMDB14878</accession>
      </metabolite>
      <reference>
        <reference_text>Schwartz G, Fehlings MG: Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog Brain Res. 2002;137:177-90.</reference_text>
        <pubmed_id>12440368</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Riluzole</name>
        <accession>HMDB14878</accession>
      </metabolite>
      <reference>
        <reference_text>Song JH, Huang CS, Nagata K, Yeh JZ, Narahashi T: Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels. J Pharmacol Exp Ther. 1997 Aug;282(2):707-14.</reference_text>
        <pubmed_id>9262334</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Riluzole</name>
        <accession>HMDB14878</accession>
      </metabolite>
      <reference>
        <reference_text>Weiss S, Benoist D, White E, Teng W, Saint DA: Riluzole protects against cardiac ischaemia and reperfusion damage via block of the persistent sodium current. Br J Pharmacol. 2010 Jul;160(5):1072-82.</reference_text>
        <pubmed_id>20590601</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prilocaine</name>
        <accession>HMDB14888</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prilocaine</name>
        <accession>HMDB14888</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prilocaine</name>
        <accession>HMDB14888</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethotoin</name>
        <accession>HMDB14892</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethotoin</name>
        <accession>HMDB14892</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethotoin</name>
        <accession>HMDB14892</accession>
      </metabolite>
      <reference>
        <reference_text>Lenkowski PW, Ko SH, Anderson JD, Brown ML, Patel MK: Block of human NaV1.5 sodium channels by novel alpha-hydroxyphenylamide analogues of phenytoin. Eur J Pharm Sci. 2004 Apr;21(5):635-44.</reference_text>
        <pubmed_id>15066664</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethotoin</name>
        <accession>HMDB14892</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxcarbazepine</name>
        <accession>HMDB14914</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxcarbazepine</name>
        <accession>HMDB14914</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxcarbazepine</name>
        <accession>HMDB14914</accession>
      </metabolite>
      <reference>
        <reference_text>Vohora D, Saraogi P, Yazdani MA, Bhowmik M, Khanam R, Pillai KK: Recent advances in adjunctive therapy for epilepsy: focus on sodium channel blockers as third-generation antiepileptic drugs. Drugs Today (Barc). 2010 Apr;46(4):265-77.</reference_text>
        <pubmed_id>20502724</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzonatate</name>
        <accession>HMDB15006</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzonatate</name>
        <accession>HMDB15006</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzonatate</name>
        <accession>HMDB15006</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cocaine</name>
        <accession>HMDB15043</accession>
      </metabolite>
      <reference>
        <reference_text>Antzelevitch C: Brugada syndrome.  Pacing Clin Electrophysiol. 2006 Oct;29(10):1130-59.</reference_text>
        <pubmed_id>17038146</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cocaine</name>
        <accession>HMDB15043</accession>
      </metabolite>
      <reference>
        <reference_text>Satish OS, Yeh KH, Wen MS: Brugada syndrome--an update.  Chang Gung Med J. 2005 Feb;28(2):69-76.</reference_text>
        <pubmed_id>15880981</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cocaine</name>
        <accession>HMDB15043</accession>
      </metabolite>
      <reference>
        <reference_text>Wright SN, Wang SY, Xiao YF, Wang GK: State-dependent cocaine block of sodium channel isoforms, chimeras, and channels coexpressed with the beta1 subunit. Biophys J. 1999 Jan;76(1 Pt 1):233-45.</reference_text>
        <pubmed_id>9876137</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Stokoe KS, Thomas G, Goddard CA, Colledge WH, Grace AA, Huang CL: Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/Delta murine hearts modelling long QT syndrome 3. J Physiol. 2007 Jan 1;578(Pt 1):69-84. Epub 2006 Oct 5.</reference_text>
        <pubmed_id>17023504</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Itoh H, Shimizu M, Takata S, Mabuchi H, Imoto K: A novel missense mutation in the SCN5A gene associated with Brugada syndrome bidirectionally affecting blocking actions of antiarrhythmic drugs. J Cardiovasc Electrophysiol. 2005 May;16(5):486-93.</reference_text>
        <pubmed_id>15877619</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Grant AO: Electrophysiological basis and genetics of Brugada syndrome.  J Cardiovasc Electrophysiol. 2005 Sep;16 Suppl 1:S3-7.</reference_text>
        <pubmed_id>16138883</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Napolitano C, Priori SG: Brugada syndrome.  Orphanet J Rare Dis. 2006 Sep 14;1:35.</reference_text>
        <pubmed_id>16972995</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Ohgo T, Okamura H, Noda T, Satomi K, Suyama K, Kurita T, Aihara N, Kamakura S, Ohe T, Shimizu W: Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation. Heart Rhythm. 2007 Jun;4(6):695-700. Epub 2007 Feb 20.</reference_text>
        <pubmed_id>17556186</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Sheets MF, Fozzard HA, Lipkind GM, Hanck DA: Sodium channel molecular conformations and antiarrhythmic drug affinity.  Trends Cardiovasc Med. 2010 Jan;20(1):16-21.</reference_text>
        <pubmed_id>20685573</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Tella SR, Goldberg SR: Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12.</reference_text>
        <pubmed_id>9476974</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9.</reference_text>
        <pubmed_id>20025128</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety.  Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506.</reference_text>
        <pubmed_id>18433351</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Schulze-Bonhage A: Zonisamide in the treatment of epilepsy.  Expert Opin Pharmacother. 2010 Jan;11(1):115-26.</reference_text>
        <pubmed_id>20001433</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug.  Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9.</reference_text>
        <pubmed_id>14704463</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. Epub 2009 Dec 4.</reference_text>
        <pubmed_id>19948168</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics.  Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10.</reference_text>
        <pubmed_id>15511691</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20.</reference_text>
        <pubmed_id>19557119</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Procainamide</name>
        <accession>HMDB15169</accession>
      </metabolite>
      <reference>
        <reference_text>Weiss R, Barmada MM, Nguyen T, Seibel JS, Cavlovich D, Kornblit CA, Angelilli A, Villanueva F, McNamara DM, London B: Clinical and molecular heterogeneity in the Brugada syndrome: a novel gene locus on chromosome 3. Circulation. 2002 Feb 12;105(6):707-13.</reference_text>
        <pubmed_id>11839626</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Procainamide</name>
        <accession>HMDB15169</accession>
      </metabolite>
      <reference>
        <reference_text>Brugada R, Brugada J, Antzelevitch C, Kirsch GE, Potenza D, Towbin JA, Brugada P: Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation. 2000 Feb 8;101(5):510-5.</reference_text>
        <pubmed_id>10662748</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Procainamide</name>
        <accession>HMDB15169</accession>
      </metabolite>
      <reference>
        <reference_text>Chen SM, Kuo CT, Lin KH, Chiang FT: Brugada syndrome without mutation of the cardiac sodium channel gene in a Taiwanese patient. J Formos Med Assoc. 2000 Nov;99(11):860-2.</reference_text>
        <pubmed_id>11155778</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Procainamide</name>
        <accession>HMDB15169</accession>
      </metabolite>
      <reference>
        <reference_text>Brugada J, Brugada R, Brugada P: [Brugada syndrome].  Arch Mal Coeur Vaiss. 1999 Jul;92(7):847-50.</reference_text>
        <pubmed_id>10443304</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Procainamide</name>
        <accession>HMDB15169</accession>
      </metabolite>
      <reference>
        <reference_text>Brugada J, Brugada P, Brugada R: The syndrome of right bundle branch block ST segment elevation in V1 to V3 and sudden death--the Brugada syndrome. Europace. 1999 Jul;1(3):156-66.</reference_text>
        <pubmed_id>11225790</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Procainamide</name>
        <accession>HMDB15169</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tocainide</name>
        <accession>HMDB15189</accession>
      </metabolite>
      <reference>
        <reference_text>Georgijevic Milic L: [Molecular genetics in the hereditary form of long QT syndrome].  Med Pregl. 2000 Jan-Feb;53(1-2):51-4.</reference_text>
        <pubmed_id>10953551</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tocainide</name>
        <accession>HMDB15189</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propafenone</name>
        <accession>HMDB15313</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propafenone</name>
        <accession>HMDB15313</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flecainide</name>
        <accession>HMDB15326</accession>
      </metabolite>
      <reference>
        <reference_text>Nagatomo T, January CT, Makielski JC: Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide. Mol Pharmacol. 2000 Jan;57(1):101-7.</reference_text>
        <pubmed_id>10617684</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flecainide</name>
        <accession>HMDB15326</accession>
      </metabolite>
      <reference>
        <reference_text>Benhorin J, Taub R, Goldmit M, Kerem B, Kass RS, Windman I, Medina A: Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome? Circulation. 2000 Apr 11;101(14):1698-706.</reference_text>
        <pubmed_id>10758053</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flecainide</name>
        <accession>HMDB15326</accession>
      </metabolite>
      <reference>
        <reference_text>Priori SG, Napolitano C, Schwartz PJ, Bloise R, Crotti L, Ronchetti E: The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge. Circulation. 2000 Aug 29;102(9):945-7.</reference_text>
        <pubmed_id>10961955</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flecainide</name>
        <accession>HMDB15326</accession>
      </metabolite>
      <reference>
        <reference_text>Cerrone M, Crotti L, Faggiano G, De Michelis V, Napolitano C, Schwartz PJ, Priori SG: [Long QT syndrome and Brugada syndrome: 2 aspects of the same disease?].  Ital Heart J Suppl. 2001 Mar;2(3):253-7.</reference_text>
        <pubmed_id>11307783</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flecainide</name>
        <accession>HMDB15326</accession>
      </metabolite>
      <reference>
        <reference_text>Viswanathan PC, Bezzina CR, George AL Jr, Roden DM, Wilde AA, Balser JR: Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes. Circulation. 2001 Sep 4;104(10):1200-5.</reference_text>
        <pubmed_id>11535580</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flecainide</name>
        <accession>HMDB15326</accession>
      </metabolite>
      <reference>
        <reference_text>Ramos E, O'leary ME: State-dependent trapping of flecainide in the cardiac sodium channel.  J Physiol. 2004 Oct 1;560(Pt 1):37-49. Epub 2004 Jul 22.</reference_text>
        <pubmed_id>15272045</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flecainide</name>
        <accession>HMDB15326</accession>
      </metabolite>
      <reference>
        <reference_text>Shimizu W, Antzelevitch C, Suyama K, Kurita T, Taguchi A, Aihara N, Takaki H, Sunagawa K, Kamakura S: Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9.</reference_text>
        <pubmed_id>11196553</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flecainide</name>
        <accession>HMDB15326</accession>
      </metabolite>
      <reference>
        <reference_text>Liu H, Atkins J, Kass RS: Common molecular determinants of flecainide and lidocaine block of heart Na+ channels: evidence from experiments with neutral and quaternary flecainide analogues. J Gen Physiol. 2003 Mar;121(3):199-214.</reference_text>
        <pubmed_id>12601084</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flecainide</name>
        <accession>HMDB15326</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Encainide</name>
        <accession>HMDB15359</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Encainide</name>
        <accession>HMDB15359</accession>
      </metabolite>
      <reference>
        <reference_text>Starmer CF, Lastra AA, Nesterenko VV, Grant AO: Proarrhythmic response to sodium channel blockade. Theoretical model and numerical experiments. Circulation. 1991 Sep;84(3):1364-77.</reference_text>
        <pubmed_id>1653123</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Encainide</name>
        <accession>HMDB15359</accession>
      </metabolite>
      <reference>
        <reference_text>Guo J, Zhan S, Somers J, Westenbroek RE, Catterall WA, Roach DE, Sheldon RS, Lees-Miller JP, Li P, Shimoni Y, Duff HJ: Decrease in density of INa is in the common final pathway to heart block in murine hearts overexpressing calcineurin. Am J Physiol Heart Circ Physiol. 2006 Dec;291(6):H2669-79. Epub 2006 Jun 2.</reference_text>
        <pubmed_id>16751287</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Encainide</name>
        <accession>HMDB15359</accession>
      </metabolite>
      <reference>
        <reference_text>Krishnan SC, Josephson ME: ST segment elevation induced by class IC antiarrhythmic agents: underlying electrophysiologic mechanisms and insights into drug-induced proarrhythmia. J Cardiovasc Electrophysiol. 1998 Nov;9(11):1167-72.</reference_text>
        <pubmed_id>9835260</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Encainide</name>
        <accession>HMDB15359</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fosphenytoin</name>
        <accession>HMDB15417</accession>
      </metabolite>
      <reference>
        <reference_text>Swadron SP, Rudis MI, Azimian K, Beringer P, Fort D, Orlinsky M: A comparison of phenytoin-loading techniques in the emergency department.  Acad Emerg Med. 2004 Mar;11(3):244-52.</reference_text>
        <pubmed_id>15001403</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fosphenytoin</name>
        <accession>HMDB15417</accession>
      </metabolite>
      <reference>
        <reference_text>Mantegazza M, Curia G, Biagini G, Ragsdale DS, Avoli M: Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol. 2010 Apr;9(4):413-24.</reference_text>
        <pubmed_id>20298965</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fosphenytoin</name>
        <accession>HMDB15417</accession>
      </metabolite>
      <reference>
        <reference_text>Lenkowski PW, Ko SH, Anderson JD, Brown ML, Patel MK: Block of human NaV1.5 sodium channels by novel alpha-hydroxyphenylamide analogues of phenytoin. Eur J Pharm Sci. 2004 Apr;21(5):635-44.</reference_text>
        <pubmed_id>15066664</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fosphenytoin</name>
        <accession>HMDB15417</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine barbiturate</name>
        <accession>HMDB15436</accession>
      </metabolite>
      <reference>
        <reference_text>Stokoe KS, Thomas G, Goddard CA, Colledge WH, Grace AA, Huang CL: Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/Delta murine hearts modelling long QT syndrome 3. J Physiol. 2007 Jan 1;578(Pt 1):69-84. Epub 2006 Oct 5.</reference_text>
        <pubmed_id>17023504</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine barbiturate</name>
        <accession>HMDB15436</accession>
      </metabolite>
      <reference>
        <reference_text>Itoh H, Shimizu M, Takata S, Mabuchi H, Imoto K: A novel missense mutation in the SCN5A gene associated with Brugada syndrome bidirectionally affecting blocking actions of antiarrhythmic drugs. J Cardiovasc Electrophysiol. 2005 May;16(5):486-93.</reference_text>
        <pubmed_id>15877619</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine barbiturate</name>
        <accession>HMDB15436</accession>
      </metabolite>
      <reference>
        <reference_text>Grant AO: Electrophysiological basis and genetics of Brugada syndrome.  J Cardiovasc Electrophysiol. 2005 Sep;16 Suppl 1:S3-7.</reference_text>
        <pubmed_id>16138883</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine barbiturate</name>
        <accession>HMDB15436</accession>
      </metabolite>
      <reference>
        <reference_text>Napolitano C, Priori SG: Brugada syndrome.  Orphanet J Rare Dis. 2006 Sep 14;1:35.</reference_text>
        <pubmed_id>16972995</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine barbiturate</name>
        <accession>HMDB15436</accession>
      </metabolite>
      <reference>
        <reference_text>Ohgo T, Okamura H, Noda T, Satomi K, Suyama K, Kurita T, Aihara N, Kamakura S, Ohe T, Shimizu W: Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation. Heart Rhythm. 2007 Jun;4(6):695-700. Epub 2007 Feb 20.</reference_text>
        <pubmed_id>17556186</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine barbiturate</name>
        <accession>HMDB15436</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine barbiturate</name>
        <accession>HMDB15436</accession>
      </metabolite>
      <reference>
        <reference_text>Sheets MF, Fozzard HA, Lipkind GM, Hanck DA: Sodium channel molecular conformations and antiarrhythmic drug affinity.  Trends Cardiovasc Med. 2010 Jan;20(1):16-21.</reference_text>
        <pubmed_id>20685573</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine barbiturate</name>
        <accession>HMDB15436</accession>
      </metabolite>
      <reference>
        <reference_text>Tella SR, Goldberg SR: Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12.</reference_text>
        <pubmed_id>9476974</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ajmaline</name>
        <accession>HMDB15495</accession>
      </metabolite>
      <reference>
        <reference_text>Barajas-Martinez HM, Hu D, Cordeiro JM, Wu Y, Kovacs RJ, Meltser H, Kui H, Elena B, Brugada R, Antzelevitch C, Dumaine R: Lidocaine-induced Brugada syndrome phenotype linked to a novel double mutation in the cardiac sodium channel. Circ Res. 2008 Aug 15;103(4):396-404. Epub 2008 Jul 3.</reference_text>
        <pubmed_id>18599870</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ajmaline</name>
        <accession>HMDB15495</accession>
      </metabolite>
      <reference>
        <reference_text>Khodorov BI, Zaborovskaya LD: Blockade of sodium and potassium channels in the node of Ranvier by ajmaline and N-propyl ajmaline. Gen Physiol Biophys. 1983 Aug;2(4):233-68.</reference_text>
        <pubmed_id>6088360</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ajmaline</name>
        <accession>HMDB15495</accession>
      </metabolite>
      <reference>
        <reference_text>Hermida JS, Dassonvalle E, Six I, Amant C, Coviaux F, Clerc J, Herent D, Hermida A, Rochette J, Jarry G: Prospective evaluation of the familial prevalence of the brugada syndrome.  Am J Cardiol. 2010 Dec 15;106(12):1758-62.</reference_text>
        <pubmed_id>21126620</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ajmaline</name>
        <accession>HMDB15495</accession>
      </metabolite>
      <reference>
        <reference_text>Hoogendijk MG, Potse M, Vinet A, de Bakker JM, Coronel R: ST segment elevation by current-to-load mismatch: an experimental and computational study. Heart Rhythm. 2011 Jan;8(1):111-8. Epub 2010 Oct 30.</reference_text>
        <pubmed_id>20870038</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ajmaline</name>
        <accession>HMDB15495</accession>
      </metabolite>
      <reference>
        <reference_text>Leoni AL, Gavillet B, Rougier JS, Marionneau C, Probst V, Le Scouarnec S, Schott JJ, Demolombe S, Bruneval P, Huang CL, Colledge WH, Grace AA, Le Marec H, Wilde AA, Mohler PJ, Escande D, Abriel H, Charpentier F: Variable Na(v)1.5 protein expression from the wild-type allele correlates with the penetrance of cardiac conduction disease in the Scn5a(+/-) mouse model. PLoS One. 2010 Feb 19;5(2):e9298.</reference_text>
        <pubmed_id>20174578</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ajmaline</name>
        <accession>HMDB15495</accession>
      </metabolite>
      <reference>
        <reference_text>Hoogendijk MG, Potse M, Linnenbank AC, Verkerk AO, den Ruijter HM, van Amersfoorth SC, Klaver EC, Beekman L, Bezzina CR, Postema PG, Tan HL, Reimer AG, van der Wal AC, Ten Harkel AD, Dalinghaus M, Vinet A, Wilde AA, de Bakker JM, Coronel R: Mechanism of right precordial ST-segment elevation in structural heart disease: excitation failure by current-to-load mismatch. Heart Rhythm. 2010;7(2):238-48. Epub 2009 Oct 12.</reference_text>
        <pubmed_id>20022821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aprindine</name>
        <accession>HMDB15498</accession>
      </metabolite>
      <reference>
        <reference_text>Sato R, Hisatome I, Tanaka Y, Sasaki N, Kotake H, Mashiba H, Katori R: Aprindine blocks the sodium current in guinea-pig ventricular myocytes.  Naunyn Schmiedebergs Arch Pharmacol. 1991 Sep;344(3):331-6.</reference_text>
        <pubmed_id>1660104</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aprindine</name>
        <accession>HMDB15498</accession>
      </metabolite>
      <reference>
        <reference_text>Kamiya K, Kodama I, Toyama J: A combination of inactivated sodium channel blockers causes competitive interaction on dV/dtmax of single ventricular myocytes. Cardiovasc Res. 1991 Jun;25(6):516-22.</reference_text>
        <pubmed_id>1653644</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
